„DON“ compounds

Boc-DON-Gln-Ile-Val-OMe, Boc-DON

10 mg 400 € available

Art. No. B003
Synonym tert.-Butyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-LGlutaminyl-L-Isoleucinyl-L-Valinmethylester
Molecular Formula C28H47N7O9
Molecular Weight 625.7
Purity by HPLC >95 % (HPLC)
Appearance yellow solid
Solubility 1.5 mM in 2% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 4.69 mg (7.5 μmol) in 100 μl DMSO - dilute by adding 4.9 ml buffer to obtain a 1.5 mM solution.
DMSO stock solutions can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Irreversible inhibitor of tissue transglutaminase; IC50 ~ 0.3 μM
Storage store at -20°C, desiccate
Reference(s) Verhaar et al., Neurochem. Int. 2011, 58:785-93
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
McConoughey et al., EMBO Mol. Med. 2010, 2:1-22
Zeugolis et al., J. Biomed. Mater. Res. 2
010, 15:1310-20
Kristen et al., Circ. Res. 2008, 102:529-37
Mádi et al., Anal. Biochem. 2005, 343:256-62
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy